Search results for "Renal Dialysi"

showing 10 items of 118 documents

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

2021

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcome…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusinessKidney international
researchProduct

Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment

2016

Cardiorenal syndrome type 4 (CRS type 4), or chronic renocardiac syndrome, has been defined as "chronic abnormalities in renal function leading to cardiac disease" and recognizes the extreme burden of cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Even though the treatment for CVD has dramatically improved over the past decades, it still takes responsibility for up to 50% of deaths in CKD patients. For this reason, patients with CKD should be thoroughly evaluated for cardiovascular risk factors that require careful management, given the significant burden of CRS type 4 on the healthcare sys…

medicine.medical_specialty030232 urology & nephrologyRenal functionCardiorenal syndromeDisease030204 cardiovascular system & hematologyurologic and male genital diseasesLeft ventricular hypertrophyAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular risk; Chronic kidney disease; Hypertension; Left ventricular hypertrophy; Atherosclerosis; Cardio-Renal Syndrome; Disease Progression; Humans; Hypertension; Hypertrophy Left Ventricular; Renal Dialysis; Renal Insufficiency Chronic; Risk Factors; Internal Medicine03 medical and health sciences0302 clinical medicineRenal DialysisRisk FactorsInternal medicineChronic kidney diseaseCardiorenal syndrome type 4medicineInternal MedicineHumansIn patientRenal InsufficiencyRenal Insufficiency ChronicRisk factorChronicIntensive care medicineCardio-Renal Syndromebusiness.industryLeft ventricular hypertrophyHypertrophymedicine.diseaseAtherosclerosisCardiovascular riskAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular riskLeft VentricularRenocardiac SyndromeAtherosclerosiHypertensionCardiologyDisease ProgressionHypertrophy Left VentricularbusinessKidney disease
researchProduct

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

2021

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with va…

medicine.medical_specialtyCOVID19Health Toxicology and Mutagenesismedicine.medical_treatmentPopulation030232 urology & nephrologymedicine.disease_cause03 medical and health sciences0302 clinical medicineRenal DialysisSeroepidemiologic StudiesPandemicHepatitis VirusesmedicineSeroprevalenceHumanshepatitisIntensive care medicineeducationCoronavirusHepatitiseducation.field_of_studybusiness.industryTransmission (medicine)SARS-CoV-2RPublic Health Environmental and Occupational Healthvirus diseasesCOVID-19medicine.diseaseVaccinationEditorialMedicinedialysis030211 gastroenterology & hepatologyHemodialysisbusinesschronic kidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Enhanced prediction of hemoglobin concentration in a very large cohort of hemodialysis patients by means of deep recurrent neural networks.

2019

Erythropoiesis Stimulating Agents (ESAs) have become a standard anemia management tool for End Stage Renal Disease (ESRD) patients. However, dose optimization constitutes an extremely challenging task due to huge inter and intra-patient variability in the responses to ESA administration. Current data-based approaches to anemia control focus on learning accurate hemoglobin prediction models, which can be later utilized for testing competing treatment choices and choosing the optimal one. These methods, despite being proven effective in practice, present several shortcomings which this paper intends to tackle. Namely, they are limited to a small cohort of patients and, even then, they fail to…

medicine.medical_specialtyComputer scienceAnemiamedicine.medical_treatmentMedicine (miscellaneous)End stage renal diseaseTask (project management)03 medical and health sciencesHemoglobins0302 clinical medicineArtificial IntelligenceRenal DialysismedicineHumansProspective StudiesIntensive care medicine030304 developmental biology0303 health sciencesbusiness.industryDeep learningmedicine.diseaseRecurrent neural networkCohortHematinicsKidney Failure ChronicArtificial intelligenceHemodialysisNeural Networks Computerbusiness030217 neurology & neurosurgeryPredictive modellingArtificial intelligence in medicine
researchProduct

Hyperhomocysteinemia in hemodialysis patients: Is it a risk factor for cardiovascular disease?

2005

medicine.medical_specialtyHyperhomocysteinemiabusiness.industrymedicine.medical_treatmentBiomedical EngineeringHyperhomocysteinemiaMedicine (miscellaneous)BioengineeringMembranes ArtificialGeneral MedicineDiseasemedicine.diseaseBiomaterialsCardiovascular DiseasesRenal DialysisRisk FactorsInternal medicinemedicineHumansHemodialysisRisk factorbusiness
researchProduct

Effects of exercise programs on physical function and activity levels in patients undergoing hemodialysis: a randomized controlled trial

2021

Background There are still many barriers when implementing exercise routines within daily dialysis care, even though benefits are well-known. Developing cost-effective strategies is necessary to overcome these barriers and include exercise as a complementary therapy in dialysis. Aim To compare several exercise programs on hemodialysis patient's functional capacity and health-related quality of life. Design This study was a 16-week follow-up, two-parallel group trial with balanced randomization. Setting Participants in this study belonged to a private hospitalized care center. Population Referred sample of 71 patients that suffered end-stage chronic kidney disease who underwent hemodialysis …

medicine.medical_specialtyRandomizationmedicine.medical_treatmentPopulationPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionQuality of life (healthcare)Randomized controlled trialRenal DialysislawHumansMedicineeducationExerciseDialysisAgededucation.field_of_studyRehabilitationbusiness.industryRehabilitationmedicine.diseaseExercise TherapyHemodialysis Units HospitalQuality of LifePhysical therapyHemodialysisbusinessKidney diseaseEuropean Journal of Physical and Rehabilitation Medicine
researchProduct

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

2013

article i nfo Introduction: The efficacy of statin treatment in chronic kidney disease (CKD) patients remains controversial. Therefore, we performed a meta-analysis to investigate whether statins modulate renal function in patients with CKD. Methods: Data from Scopus, PubMed, Web of Science, and the Cochrane Central Register of randomized controlled trials for years 1966-December 2012 were searched for appropriate studies. Results: Twenty trials with 6452 CKD subjects randomized to receive either statin or placebo were included. Statin therapy significantly influenced high sensitivity C-reactive protein levels in patients on or off dialysis (−0.28 mg/dl, 95%CI: −0.93 to −0.37; p b 0.05 and …

medicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentRenal functionPlaceboGastroenterologyBlood Urea Nitrogenlaw.inventionchemistry.chemical_compoundRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicinechronic kidney disease creatinine dialysis meta-analysis renal outcomes statin urinary proteinDialysisRandomized Controlled Trials as TopicCreatininebusiness.industrymedicine.diseaseTreatment OutcomechemistryCardiovascular DiseasesCreatinineMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateKidney disease
researchProduct

Video-assisted two-stage basilic vein transposition for creation of brachio-basilic arteriovenous fistulae

2012

We report our experience in a mixed minimally-in- vasive technique for the two-stage transposition of basilic vein on a small series of eight patients. The operative tech- nique consisted of a modified endoscopic (1) approach for the two-stage transposition (2). The intervention was performed under Brachial Plexus Block (3).

medicine.medical_specialtyTime FactorsBasilic VeinTreatment outcomeOperative TimeArteriovenous fistula; End Stage Renal Disease; Video-assisted surgeryVideo-assisted surgerySettore MED/22 - Chirurgia VascolareSurgical methodsVeinsTransposition (music)Upper ExtremityArteriovenous Shunt SurgicalRenal DialysismedicineHumansVideo assistedVascular PatencyArteriovenous fistulabusiness.industryEndoscopyBrachial Plexus BlockSurgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeSurgery Computer-AssistedNephrologyOperative timeSurgeryEnd Stage Renal Diseasebusiness
researchProduct

Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function

1978

Infusions of 3.5% isocyanate cross-linked polypeptide solution 500 ml were given to 52 patients with normal or impaired renal function: glomerular filtration rate (GFR)=0–133 ml/min. The serum concentration and urinary excretion of hydroxyproline were measured and the equivalent polypeptide concentrations were calculated from the results. In patients with normal renal function (GFR>90 ml/min) the proportion of polypeptide excreted in the urine up to 12 h was 45.4±2.6% ( $$\bar X$$ ±SEM), up to 24 h 47.7±2.9% and up to 48 h 49.3±3.4%. In patients with moderate renal insufficiency (GFR=30–90 ml/min) there was no decrease in polypeptide excretion and even in patients with more serious impairme…

medicine.medical_specialtyTime FactorsUrinary systemPlasma SubstitutesRenal functionUrine030204 cardiovascular system & hematologyurologic and male genital diseasesExcretion03 medical and health sciencesHydroxyprolinechemistry.chemical_compound0302 clinical medicinePharmacokineticsRenal Dialysis030202 anesthesiologyInternal medicinemedicineHumansPharmacology (medical)CyanatesPharmacologyChemistryHalf-lifeGeneral Medicine3. Good healthKineticsEndocrinologyKidney DiseasesPeptidesHaemaccelGlomerular Filtration RateHalf-LifeEuropean Journal of Clinical Pharmacology
researchProduct